The BCDD at the BioMed@TAU Rare Diseases Hub Symposium

The talks focused on in silico prediction of FDA approved drugs for a rare disease

30 May 2018
The BCDD at the BioMed@TAU Rare Diseases Hub Symposium

BLAVATNIK CENTER for Drug Discovery presented yesterday its activity at the "Rare Diseases: From Patients to Bench and Back" symposium.

 

The event was organized by the Research Hub in Rare Diseases at Tel Aviv University in collaboration with the Sheba Medical Center’s Institute of Rare Diseases.

 

Adva Yeheskel, a research fellow of the Computer-Aided Drug Design Unit at the BCDD, reviewed the BCDD three units, their expertise and contact members. The talk, under the title "Small molecule Design Based on Mutation Analysis - Personalized Medicine Approach", was focused on in silico prediction of FDA approved drugs for a rare disease named STXBP1.

 

Click here for the BioMed @ TAU Hub in Rare Diseases >>

Click Here for the full symposium program >>

Tel Aviv University, P.O. Box 39040, Tel Aviv 6997801, Israel
UI/UX Basch_Interactive